Incorporating AI into Commercialization Plans

Despite challenges surrounding communication overload, drug shortages, and cybersecurity risks, this term is revolutionizing medication management and patient care through the use artificial intelligence and predictive forecasting.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

The move—one that meet’s industry standards—confirms the Cryoport company’s commitment to providing quality and safety in the cold chain solutions space.